

Annex III

Amendments to relevant sections of the summaries of product characteristics and package leaflets

A. Summary of Product Characteristics

4.1 Therapeutic indications

[the below currently approved indications should be deleted (specific wording of the indication may vary from product to product)]

- Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)
- Ancillary treatment of Raynaud's syndrome
- Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin
- Prophylaxis of migraine headache
- Symptomatic treatment of veno-lymphatic insufficiency

All references to the above mentioned indications should be deleted from the remaining relevant sections of the summaries of product characteristics.

B. Package Leaflet

All references to the above mentioned indications should be deleted from the relevant sections of the package leaflets.